Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Alpha-1 Antitrypsin Deficiency Clinical Trials
Alpha-1 Antitrypsin Deficiency clinical trials are recruiting across 16 cities. Here are the cities with the most active studies:
Alpha-1 Antitrypsin Deficiency Trial Phases
5 research organizations are sponsoring alpha-1 antitrypsin deficiency trials.
About Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency is a genetic condition that increases the risk of lung and liver disease due to low levels of the protective protein alpha-1 antitrypsin. It is one of the most common genetic causes of COPD. Treatment includes augmentation therapy and management of lung and liver symptoms.
Clinical trials are advancing new treatments for alpha-1 antitrypsin deficiency. Currently, 8 studies are recruiting a combined 51,123 participants across the United States. Research is being conducted by 5 organizations including University of Florida, Takeda, Beam Therapeutics Inc. and 2 others.
2026 Alpha-1 Antitrypsin Deficiency Research Landscape
As of July 2026, the alpha-1 antitrypsin deficiency clinical trial landscape includes 8 actively recruiting studies across 16 cities in the United States. These studies are collectively seeking 51,123 participants, with an average enrollment target of 6,390 per study.
The research spans multiple phases of development: 3 studies are in PHASE1, 2 studies are in PHASE3, 2 studies are in PHASE2. The presence of Phase 3 trials indicates that some alpha-1 antitrypsin deficiency treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 5 different organizations, including University of Florida, Takeda, Beam Therapeutics Inc., Tessera Therapeutics, Inc., Krystal Biotech, Inc..
Geographically, alpha-1 antitrypsin deficiency trials are most concentrated in Gainesville, Florida (5 trials); Boston, Massachusetts (3 trials); Charleston, South Carolina (3 trials); Birmingham, Alabama (2 trials); Phoenix, Arizona (2 trials) and 7 other cities.
Featured Alpha-1 Antitrypsin Deficiency Studies
Highlighted recruiting studies for alpha-1 antitrypsin deficiency, selected by enrollment size and research scope.
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
The main aim of this study is to learn about liver problems caused by the lack of alpha-1 antitrypsin (called Alpha-1 Antitrypsin Deficiency or AATD) in adults when not treated (this is called the natural history of a condition) over 5 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently being diagno...
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
Frequently Asked Questions About Alpha-1 Antitrypsin Deficiency Clinical Trials
Are there alpha-1 antitrypsin deficiency clinical trials near me?
Yes, there are 8 alpha-1 antitrypsin deficiency clinical trials currently recruiting across 16+ cities in the United States, including Gainesville, Florida; Boston, Massachusetts; Charleston, South Carolina. Browse the studies above to find one at a location convenient for you.
How do I join a alpha-1 antitrypsin deficiency clinical trial?
To join a alpha-1 antitrypsin deficiency clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are alpha-1 antitrypsin deficiency clinical trials free?
Yes, participation in alpha-1 antitrypsin deficiency clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of alpha-1 antitrypsin deficiency treatments are being studied?
Current alpha-1 antitrypsin deficiency clinical trials are testing a range of approaches across PHASE1 (3 studies), PHASE3 (2 studies), PHASE2 (2 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in alpha-1 antitrypsin deficiency clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov